Abstract: The present invention relates to an immunoassay method for the detection of Chromogranin A (or fragment(s) thereof) comprising the steps of contacting a sample suspected of comprising Chromogranin A with a first antibody or an antigen-binding fragment or derivative thereof specific for Chromogranin A and a second antibody or an antigen-binding fragment or derivative thereof specific for Chromogranin A under conditions allowing for the formation of a ternary complex between Chromogranin A and the two antibodies or antigen-binding fragments or derivates thereof, and detecting the binding of the two antibodies or antigen-binding fragments or derivates thereof to Chromogranin A. Also provided are antibodies directed against amino acid residues 124 to 144 and 280 to 301 of Chromogranin A and their use in the immunoassay method.

Abstract: The present invention relates to an immunoassay method for placental growth factor 2 (PlGF-2) detection in pregnant subjects. Furthermore the invention relates to the use of said method for the diagnosis, prognosis, risk assessment and therapy control of prenatal disorders comprising the determination of the level of PlGF-2 in said pregnant subjects.

Abstract: The present invention relates to an immunoassay method for the detection of Chromogranin A (or fragment(s) thereof) comprising the steps of contacting a sample suspected of comprising Chromogranin A with a first antibody or an antigen-binding fragment or derivative thereof specific for Chromogranin A and a second antibody or an antigen-binding fragment or derivative thereof specific for Chromogranin A under conditions allowing for the formation of a ternary complex between Chromogranin A and the two antibodies or antigen-binding fragments or derivates thereof, and detecting the binding of the two antibodies or antigen-binding fragments or derivates thereof to Chromogranin A. Also provided are antibodies directed against amino acid residues 124 to 144 and 280 to 301 of Chromogranin A and their use in the immunoassay method.

Abstract: The present invention relates to an immunoassay method for placental growth factor 2 (PlGF-2) detection in pregnant subjects. Furthermore the invention relates to the use of said method for the diagnosis, prognosis, risk assessment and therapy control of prenatal disorders comprising the determination of the level of PlGF-2 in said pregnant subjects.

Abstract: The present invention relates to the prognosis and risk assessment in pregnant women to develop pregnancy-induced hypertension and/or preeclampsia by the determination of marker levels.

Abstract: The present invention relates to the use of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity, or of circulating anti-MMP-7 antibodies, as humoral biomarkers in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of renal cell carcinoma (RCC) in human patients.

Abstract: The present invention relates to the use in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of metastatic bladder cancer in human patients of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity that can be measured in blood, serum or plasma samples from the patient.

Abstract: The present invention relates to the use of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity, or of circulating anti-MMP-7 antibodies, as humoral biomarkers in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of renal cell carcinoma (RCC) in human patients.